ZS publishes practice cases about airlines and sunscreen. That is how candidates walk into a ZS case interview expecting a McKinsey-style issue tree, then stall when the exhibit is a call plan, a promotion-response curve, or a launch forecast with three decimal places of gross-to-net. The thesis is simple: for most campus consulting seats, ZS is scoring commercial-analytics judgment in life sciences, not generalist structuring theatre. After this piece you should be able to run a sales-force sizing case to a recommendation with units that survive a partner's pushback.
ZS is a management consulting and technology firm founded in 1983, with more than 13,000 people in over 35 offices as of its January 2026 fact sheet. Its public capabilities lean hard into healthcare commercialization: territory design, resource deployment, marketing analytics, value and access. That is the work. The interview mirrors it even when the sample PDF does not.
What ZS says about its own process
Start with the firm's pages, not folklore. ZS describes a process that typically runs two to four rounds, varying by role, level, and region. Stages can include an online assessment (logical, quantitative, and qualitative reasoning, plus data and coding concepts for some tracks), behavioral interviews, case interviews, and subject-matter expertise interviews. Certain roles require the online assessment; your recruiter is the source of truth for the exact mix.
On cases, ZS is explicit about what it wants to see: structure a business challenge, develop solutions, apply feedback, and think creatively. There is no claim of a single "correct" answer. That language matters. Interviewers at analytics-heavy firms often care less about whether you guessed the framework they had in mind and more about whether you can revise a model when they add a constraint.
Jobs-board titles such as Commercial Pharma Analytics Associate Consultant and Decision Analytics Associate Consultant–Commercial sit next to Emerging Pharma tracks. Data science seats add SQL and coding depth; this guide is for the consulting and decision-analytics path.
Why the practice cases mislead MBB-trained candidates
ZS's published practice set includes All-Star Airlines market entry, a pharmaceutical pricing case (Zoltners / SINHA for COPD), and a consumer-goods sunscreen launch. Prep only on the airline and sunscreen prompts and you will look fluent in profit trees. That is useful. It is also incomplete.
Live ZS work, as the firm markets it, centers on commercial model design: sizing and shifting teams, designing territories, connecting targeting analytics to field behavior, and measuring what actually moves performance. In the room, that shows up as:
| Dimension | Typical MBB first-round case | Typical ZS consulting case |
|---|---|---|
| Industry | Any industry that fits a clean tree | Pharma, biotech, medtech, adjacent commercial |
| Core question | Enter? Grow? Cut cost? | How many reps, which targets, what promotion mix |
| Exhibits | One or two clean tables | Dense tables: TRx/NRx, deciles, reach/frequency, costs |
| Success metric | Profit, NPV, market share | Incremental starts or net revenue vs fully loaded cost |
| Causal claim | Often left fuzzy | Explicit: do not treat association as response |
The McKinsey-trained failure mode is predictable. You open with 3C or a market-entry MECE tree. You maximize "share of voice" as if more calls always mean more sales. You treat TRx as revenue. You never mention gross-to-net. You recommend a five percent price cut because that is what you practiced last week. The interviewer, who has lived inside promotion-response models, stops taking notes.
The vocabulary the scoring sheet rewards
You do not need a PhD in pharmacoeconomics. You do need to speak the units without blushing:
- TRx / NRx. Total and new prescriptions. Starts and switches are not the same as refill volume.
- Reach and frequency. How many target HCPs you touch, and how often, in a period.
- Call plan and no-see rate. Planned calls versus productive ones after access friction.
- Deciles / tiers. Not all writers are equal; the top tier usually carries most volume.
- Gross-to-net. List price is not cash. Rebates, discounts, and channel fees matter.
- Analog brand. Your response curve is borrowed from a prior launch; say so out loud.
- MSL vs sales vs digital. Do not double-count the same HCP across channels.
I stop listening when a candidate builds a beautiful structure and never defines the decision metric. "Optimize the sales force" is not a metric. "Maximize year-1 contribution after fully loaded field cost" is.
Ned's rule. In a ZS-style commercial case, force every option through one equation: incremental patient-years (or starts) times contribution per start, minus incremental fully loaded cost. If you cannot write that on the page in thirty seconds, you are still doing MBB theatre.
Mini-case: Medora's ulcerative colitis launch (worked)
This case is invented. The numbers are internally consistent so you can reproduce the arithmetic. It is not a ZS confidential prompt.
Prompt. Medora Therapeutics will launch an oral therapy for moderate ulcerative colitis in the US. There are about 8,500 gastroenterologists who write relevant scripts. Leadership wants a year-1 field plan. Options on the table: 45, 65, or 90 specialty reps. Each rep averages 7 calls per day over 210 workdays. Fully loaded cost is $265,000 per rep per year. Net contribution after gross-to-net and COGS is $42,000 per incremental patient-year. Top 3,000 writers account for roughly 70% of addressable volume. Should Medora staff 45, 65, or 90?
Clarify first. Success is year-1 contribution, not vanity share of voice. Contract sales and digital detailing are allowed as options, but today leadership wants a field-headcount recommendation. Frequency caps exist: above about 18 calls per year on the same HCP, response flattens.
Capacity (state it before the response story).
| Reps | Gross calls/year (reps × 7 × 210) | After 15% no-see / waste | Productive calls |
|---|---|---|---|
| 45 | 66,150 | × 0.85 | ~56,200 |
| 65 | 95,550 | × 0.85 | ~81,200 |
| 90 | 132,300 | × 0.85 | ~112,500 |
Covering the top 3,000 at 12 calls each needs 36,000 productive calls. All three plans have the capacity to cover that tier. The decision is not raw capacity. It is where the next call lands on a diminishing response curve.
Response curve (state the assumption). Borrowed from an analog oral GI launch (say so):
| Calls/year on a high-tier HCP | Expected patient-years started |
|---|---|
| 0 | 0.25 |
| 6 | 0.85 |
| 12 | 1.15 |
| 18 | 1.28 |
Moving from 0 to 12 calls lifts +0.90 patient-years. Moving from 12 to 18 lifts only +0.13 more. That asymmetry is the case.
Compare plans (illustrative, not a full Monte Carlo).
- 45 reps (~56k productive calls). You cover the top ~3,000 at roughly 12–14 calls and barely touch the next tier. Baseline: treat this as the "tight list" plan. Suppose it delivers 2,400 incremental patient-years versus a no-field counterfactual. Contribution: 2,400 × $42k = $100.8m. Field cost: 45 × $265k = $11.9m. Net vs no field: about $88.9m.
- 65 reps (~81k productive calls). You keep top-tier frequency near 12–14 and buy meaningful reach into the next ~2,000 writers at lower frequency. Suppose that adds +380 patient-years versus the 45-rep plan (mostly mid-tier writers, some lift from better access). Incremental contribution: 380 × $42k = $16.0m. Incremental cost: 20 × $265k = $5.3m. Incremental net: about $10.7m. 65 beats 45.
- 90 reps (~112k productive calls). Most of the extra ~31k productive calls go to frequency on already-covered high tiers (12 → 16–18) plus thin long-tail coverage. Optimistic lift versus 65: about +420 patient-years. Contribution: 420 × $42k = $17.6m. Incremental cost: 25 × $265k = $6.6m. If the analog overstates mid-tier response by a third, lift falls to
280 starts ($11.8m contribution against $6.6m cost). Competitive presence can argue for some of the jump; pure year-1 contribution usually does not need all 90.
Recommendation. Prefer 65 reps with a tight top-3,000 list at ~12 calls, a thinner mid-tier plan, and a digital/MSL plan for the long tail. Do not default to 90 to "show commitment." Flag the analog risk: if the prior launch had easier office access, your productive-call assumption is too rosy. Next step is not a prettier MECE tree; it is the client's analog reach-frequency tables and a sensitivity on contribution per start (±20%).
That is the shape of a ZS-flavored answer: units, diminishing returns, cost of the next rep, and an honest assumption label.
How this differs from MBB in the first five minutes
At MBB you often win the opening by framing a broad problem tree the interviewer can walk. At ZS you often win by naming the commercial decision, the units, and the dirty data issues before you draw anything.
| Minute | MBB-style move | Stronger ZS move |
|---|---|---|
| 0–1 | Restate and broad framework | Restate metric: contribution vs fully loaded cost |
| 1–3 | Issue tree with four buckets | Universe → response → access → cost → channel mix |
| 3–5 | Ask for "more data" vaguely | Ask for call capacity, no-see, analog curve, gross-to-net |
| Close | Crisp "I recommend enter" | Option table with sensitivity on the analog |
Creativity still counts—ZS says so on its careers pages—but creativity here means a smarter target list or a hybrid field/digital mix, not a surprise pivot into corporate strategy.
What to practice before Super Day
- Rebuild the Medora math with your own response curve. Change one assumption at a time and watch which plan flips.
- Drill chart reading under time pressure. ZS exhibits are denser than textbook cases; precision beats narrative.
- Learn to say "I am treating association as causal only under assumption X." That sentence alone separates analytics hires from framework reciters.
- Behavioral: a time you changed a model when the first specification was wrong. Messy data stories travel well here.
Drill this on CoachNed today
Run one healthcare-flavored case on /start (three typed turns, instant scores, no account required) and force yourself to close with a contribution-versus-cost recommendation. Then do a timed pass on /drills/math and /drills/charts so dense tables do not slow you down. If you want a full voice debrief, use /interview (CopperCup, about 18 minutes, seven-score feedback). Everything is open for seven days with no card; then $120 for a recruiting season or $49 a month. CoachNed cases are practice gyms, not ZS replicas—debrief in commercial-analytics language either way.
Frequently asked questions
Does ZS only interview on pharmaceutical cases?
No. The firm's own practice library includes airlines and consumer goods, and process details vary by role. For consulting and commercial analytics seats, expect life-sciences commercial judgment to show up often because that is a large share of the firm's public positioning.
How many interview rounds does ZS run?
ZS states that candidates can typically expect two to four rounds, depending on role, level, region, and other factors. Confirm the sequence with your recruiter rather than assuming a fixed campus template.
Do I need a PhD or advanced statistics background?
Not for many consulting and decision-analytics associate paths. Data science and technical tracks raise the bar on coding, SQL, and analytics concepts. Match prep to the job description you applied to.
Are ZS cases candidate-led or interviewer-led?
Formats vary. Even when the interviewer drives with exhibits, you are still expected to structure, quantify, and revise when given feedback. Waiting silently for the next slide is a common miss.
Where should I get official prep material?
Use ZS's own interview process and case practice pages. Treat sample cases as style guides, not as a promise your live prompt will be an airline. CoachNed is independent and not affiliated with ZS Associates, McKinsey, BCG, Bain, or any other firm named here for interview practice.
Sources
- ZS Interview Process — rounds, assessment types, case evaluation language. Checked 2026-09-24.
- Case interview practice tests | ZS — published practice cases (airlines, pharma pricing, sunscreen). Checked 2026-09-24.
- ZS Fact Sheet (January 2026) — founding year, headcount, office footprint. Checked 2026-09-24.
- Commercial Model Design & Operations | ZS — territory sizing, resource deployment, commercial analytics focus. Checked 2026-09-24.
- Healthcare industry insights | ZS — life-sciences and commercialization emphasis. Checked 2026-09-24.